Bristol Myers Squibb in an all-cash deal at $5 per share, with the merger set to close in Q2 2025. Despite Abecma generating $242 million in U.S. sales, 2seventy still booked a $3.3 million loss from ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Shares of Bristol Myers Squibb Co. slid 3.05% to $59.19 Tuesday, on what proved to be an all-around favorable trading session ...

CAMBRIDGE, Mass., March 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights ...

"It’s as much of the marquee high-value transactions as it is the aggregation of what we call our bread and butter, and it’s ...

Bearish flow noted in Bristol Myers ( BMY) Squibb with 13,765 puts trading, or 2x expected. Most active are Apr-25 60 puts and 4/4 weekly 60 puts, with total volume in those strikes near 8,600 ...

BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to ...

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

“Dr. Medvec’s strategic value to our company is significant,” said Amir Heshmatpour, NeOnc’s Executive Chairman. “We anticipate receiving significant benefits from her insights and guidance as NeOnc ...